↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Urologi och njurmedicin) ;pers:(Aus Gunnar 1958)"

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Urologi och njurmedicin) > Aus Gunnar 1958

Resultat 1-10 av 39

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Zackrisson, Björn, et al. (författare) Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. 2003 Ingår i: Urology. - 1527-9995. ; 62:2, s. 278-81 Tidskriftsartikel (refereegranskat)abstract To determine the serum values of free, complexed, and total prostate-specific antigen (PSA) and their ratios in men with febrile urinary tract infection (UTI) during 1 year of follow-up.
2.	Aus, Gunnar, 1958, et al. (författare) Editorial Comments 2008 Ingår i: J Urol. ; 4:1, s. 17-18 Recension (övrigt vetenskapligt/konstnärligt)
3.	Frånlund, Maria, et al. (författare) The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial. 2012 Ingår i: BJU international. - 1464-410X. ; 110:5, s. 638-43 Tidskriftsartikel (refereegranskat)abstract What's known on the subject? and What does the study add? There are only a few studies and no consensus concerning the relationship between LUTS and prostate cancer. This paper focuses on 2353 men with an elevated PSA level within the Gothenburg Randomized Screening Trial who underwent biopsy and answered questions regarding LUTS. The main conclusion was that the absence of voiding symptoms is an independent risk factor for prostate cancer detection.
4.	Grenabo Bergdahl, Anna, et al. (författare) Corrigendum re: "Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial" [Eur Urol 2016;70:566-73]. 2017 Ingår i: European urology. - : Elsevier BV. - 1873-7560 .- 0302-2838. ; 71:2 Annan publikation (övrigt vetenskapligt/konstnärligt)
5.	Grenabo Bergdahl, Anna, et al. (författare) Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial. 2016 Ingår i: European urology. - : Elsevier BV. - 1873-7560 .- 0302-2838. ; 70:4, s. 566-573 Tidskriftsartikel (refereegranskat)abstract Magnetic resonance imaging (MRI) and targeted biopsies (TB) have shown potential to more accurately detect significant prostate cancer compared with prostate-specific antigen (PSA) and systematic biopsies (SB).
6.	Hugosson, Jonas, 1955, et al. (författare) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. 2010 Ingår i: The lancet oncology. - 1474-5488. ; 11:8, s. 725-32 Tidskriftsartikel (refereegranskat)abstract Prostate cancer is one of the leading causes of death from malignant disease among men in the developed world. One strategy to decrease the risk of death from this disease is screening with prostate-specific antigen (PSA); however, the extent of benefit and harm with such screening is under continuous debate.
7.	Schröder, Fritz H, et al. (författare) Screening and prostate-cancer mortality in a randomized European study. 2009 Ingår i: The New England journal of medicine. - 1533-4406 .- 0028-4793. ; 360:13, s. 1320-8 Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer.
8.	Schröder, Fritz H, et al. (författare) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. 2014 Ingår i: Lancet. - 1474-547X. ; 384:9959, s. 2027-2035 Tidskriftsartikel (refereegranskat)abstract The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis. We provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years.
9.	Vickers, Andrew J, et al. (författare) Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. 2010 Ingår i: Cancer. - : Wiley. - 0008-543X .- 1097-0142. ; 116:11, s. 2612-20 Tidskriftsartikel (refereegranskat)abstract Risk models to predict prostate cancer on biopsy, whether they include only prostate-specific antigen (PSA) or other markers, are intended for use in all men of screening age. However, the association between PSA and cancer probably depends on a man's recent screening history.
10.	Aus, Gunnar, 1958 (författare) Current status of HIFU and cryotherapy in prostate cancer--a review. 2006 Ingår i: Eur Urol. - : Elsevier BV. ; 50:5, s. 927-934 Tidskriftsartikel (refereegranskat)abstract Objectives To evaluate the current status of high-intensity focused ultrasound (HIFU) and cryosurgery as the primary treatment option in patients with prostate cancer. Method A MedLine search using specified search terms was done on February 28, 2005. This search rendered 150 papers related to HIFU and 566 papers related to cryosurgery. Very few of these papers presented original outcome data and are included in the present review. Results No controlled trial was available for analysis, and no survival data were presented. No validated biochemical, surrogate end point was available for any of the two therapies. HIFU showed progression-free survival (based on prostate-specific antigen ± biopsy data) of 63–87% (projected 3- to 5-yr data), but median follow-up in the studies ranged from 12–24 mo. Negative postoperative biopsies was seen in 82–94% of patients. Complications have been reduced by the combination of transurethral resection of the prostate and HIFU. Cryosurgery showed a progression-free survival of 36–92% (projected 1–7 yr data), depending on risk groups and definition of failure. Negative biopsies were seen in 72–87%, but no biopsy data were available for the currently used third-generation cryotherapy machines. Complications seem to be lower with the third-generation machines. Conclusions None of the evaluated therapies has enough data available to support their use as an alternative to established therapies (surgery, radiation) for localised prostate cancer. Until further data become available, the use of both treatments should be restricted to patients unfit for established therapies who still have the need for local therapy. Take Home Message Both HIFU and cryotherapy are used in the treatment of prostate cancer, but there is a profound lack of long-term follow-up data for the currently used treatment modalities. Their use should be limited to patients unfit for conventional therapies.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-10 av 39

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (35); recension (2); annan publikation (1); forskningsöversikt (1)

Typ av innehåll: refereegranskat (34); övrigt vetenskapligt/konstnärligt (5)

Författare/redaktör: Aus, Gunnar, 195... (39)Ta bort avgränsningen; Hugosson, Jonas, 195 ... (23); Carlsson, Sigrid, 19 ... (10); Stranne, Johan, 1970 (9); Lilja, Hans (8); Khatami, Ali, 1975 (8); visa fler...; Schröder, Fritz H (8); Roobol, Monique J (7); Damber, Jan-Erik, 19 ... (7); Bergdahl, Svante, 19 ... (6); Lodding, Pär, 1957 (6); Tammela, Teuvo L.J. (5); Bangma, Chris H (5); Auvinen, Anssi (4); Zappa, Marco (4); Denis, Louis J (4); Nelen, Vera (4); Kwiatkowski, Maciej (4); Lujan, Marcos (4); Moss, Sue M (4); Holmberg, Erik, 1951 (3); Moul, JW (3); Taari, Kimmo (3); Paez, Alvaro (3); de Koning, Harry J (3); Thompson, I. (3); Villers, Arnauld (3); Burnett, AL (3); Canby-Hagino, ED (3); Cookson, MS (3); D'Amico, AV (3); Dmochowski, RR (3); Eton, DT (3); Forman, JD (3); Goldenberg, SL (3); Higano, CS (3); Thrasher, JB (3); Berterö, Carina (2); Lilja, H. (2); Wilderäng, Ulrica (2); Hellström, Mikael, 1 ... (2); Hakama, Matti (2); Vickers, Andrew J. (2); Puliti, Donella (2); van der Kwast, Theod ... (2); Hernández, J. (2); Scardino, Peter T. (2); Geterud, Kjell (2); Cronin, Angel M (2); Tangen, C (2); visa färre...

Lärosäte: Göteborgs universitet (39); Lunds universitet (8); Linköpings universitet (4); Uppsala universitet (1)

Språk: Engelska (39)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (39)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy